Abstract
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) effectively treat patients with non-small cell lung cancer (NSCLC) with EGFR-sensitizing mutations; however, almost all will eventually relapse due to new mutations on or after osimertinib the 3rd generation TKI. The current standard of care is platinum doublet chemotherapy after progression on osimertinib, but with limited benefit. Amivantamab, an EGFR and MET bispecific humanized antibody, has shown clinical activity against tumors with primary activating EGFR mutations, EGFR resistance mutations, or MET pathway activation.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
